Janux Therapeutics, Inc. (JANX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$20.24+2.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JANX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 24.0 | 10.0 | 10.6 | 8.1 | 8.6 | 3.6 | 0.0 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 124.0 | 125.9 | 68.4 | 54.9 | 53.4 | 26.2 | 3.0 |
| Operating Income | (143.6) | (157.7) | (98.8) | (73.0) | (67.1) | (32.9) | (4.8) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 41.0 | 44.0 | 29.9 | 14.7 | 4.0 | 0.3 | (1.9) |
| Income Tax Expense | — | — | — | 0.0 | — | — | — |
| Net Income | |||||||
| Net Income | (102.6) | (113.6) | (69.0) | (58.3) | (63.1) | (32.7) | (6.8) |
| Per Share | |||||||
| Basic EPS | (1.63) | (1.83) | (1.28) | (1.32) | (1.52) | (1.39) | — |
| Diluted EPS | (1.63) | (1.83) | (1.28) | (1.32) | (1.52) | (1.39) | — |
| Revenue per Share | 0.38 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 62.9 | 62.0 | 53.8 | 44.0 | 41.5 | 23.5 | 0.2 |
| Diluted Weighted Avg Shares | 62.9 | 62.0 | 53.8 | 44.0 | 41.5 | 23.5 | — |
| Supplemental | |||||||
| EBIT | (143.6) | (157.7) | (98.8) | (73.0) | (67.1) | (32.9) | (4.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.